TAC01-ROR1

N/A

Report date: 2025/01/26 16:30:51

Base Information

Drug NameTAC01-ROR1

Drug Alias Nameanti-ROR1 TAC T-cell therapy (Triumvira Immunologics)TAC01-ROR1

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionInactive tyrosine-protein kinase transmembrane receptor ROR1 modulators

TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1

Therapy Area/IndicationsLung NeoplasmsColonic NeoplasmsBreast Neoplasms +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTriumvira Immunologics Inc

China Registration ClassN/A

Develop Information

Active CompaniesTriumvira Immunologics Inc

Inactive CompaniesN/A

Active IndicationsLung NeoplasmsColonic NeoplasmsBreast Neoplasms

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A